P/B
2,1
CervoMed
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
$48.7M
Market Cap • 10/9/2026
1995
(31 years)
Founded
1996
(30 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
146,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,5
EPS
—
Market Cap
Market Cap
48,7M
EV
23,7M
EV/Revenue
71,7
EV/EBITDA
-0,8
EV/EBIT
-0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-112,2M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
6437,7%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
17,2%
CAGR Net Income 5Y
12,4%
CAGR EPS 5Y
-28,1%
CAGR OCF 5Y
12,7%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
8,6
Quick Ratio
8,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!